Results 91 to 100 of about 2,223,665 (257)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

BMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu, Wanghua Liu, Shao Li   +13 more
wiley   +1 more source

Endogenous protein S100A14 stabilizes glutaminase to render hepatocellular carcinoma resistant to sorafenib

Journal of Translational Medicine
Background Many cases of advanced hepatocellular carcinoma (HCC) are resistant to the widely used drug sorafenib, which worsens prognosis. While many studies have explored how acquired resistance emerges during drug exposure, the mechanism underlying ...
Menghui Wang, Yueheng Li, Junhui Su, Xinjue Dong, Ao Liu, Yuqi Yang, Xinyi Tang, Ruijie Chen, QingQuan Li, Hongshan Wang, Hong Xiao   +10 more
doaj   +1 more source

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Simon Allison, R. Rani (7694267), RANI, RESHMA, Granchi, C., John Knight, S. J. Allison (7694258), Knight, J. R.P.; id_orcid, Milner, J., Knight, J.R.P., F. Minutolo (7694270), Phillips, R.M., Jo Milner, MINUTOLO, FILIPPO, GRANCHI, CARLOTTA, Phillips, R. M., J . Milner (7694273), Allison, Simon J., Roger Phillips, Phillips, Roger M., C. Granchi (7694264), J. R. P. Knight (7694261), Rani, R., Minutolo, F., R. M. Phillips (2087326), Allison, S. J.   +24 more
core   +1 more source

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma

Molecular Oncology, 2019
Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer‐related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor.
Hui‐Huang Lai, Chih‐Wei Li, Chih‐Chen Hong, Hung‐Yu Sun, Ching‐Feng Chiu, Da‐Liang Ou, Pai‐Sheng Chen   +6 more
doaj   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Decitabine regulates the resistance of HCC to sorafenib through demethylation

Clinical Epigenetics
To evaluate the efficacy of sorafenib in combination with the DNA methylation inhibitor decitabine (DAC) for the treatment of hepatocellular carcinoma (HCC), and to investigate the mechanism of sorafenib resistance from an epigenetic perspective, aiming to provide new insights and strategies for HCC therapy.The GEPIA2 database was used to analyze the ...
Zhang, Miao, Zhou, Xiaolei, Li, Zhenzhen, Zhao, TianYu, Miao, Yu, Liu, Sen, Han, Qiaoqiao, Wang, Libo, Xu, Yongdeng, Cui, Tao, Wang, Ze, Yi, Xiulin, Yan, Fengying, Wang, Xiaoliang   +13 more
openaire   +2 more sources

Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells

, 2021
Despite liver cancer being the second-leading cause of cancer-related death worldwide, few systemic drugs have been approved. Sorafenib, the first FDA-approved systemic drug for unresectable hepatocellular carcinoma (HCC), is limited by resistance ...
Sung-Ho Kim, N R Shin, H J Lee, S C Park, Na-Rae Shin, Su-Cheol Park, Hae-June Lee, S H Kim, Yeonghoon Son   +8 more
core   +1 more source

Overriding adaptive resistance to sorafenib via combination therapy with SHP2 blockade in hepatocellular carcinoma [PDF]

, 2020
The survival benefit of sorafenib for hepatocellular carcinoma (HCC) patients is unsatisfactory due to the development of adaptive resistance. Increasing evidence has demonstrated that drug resistance can be acquired by cancer cells by activating a ...
CHE, N, Ma, S, Tang, KH, Lau, EYT, Lee, TKW, Tong, M, Leung, CON, Chung, KPS, Ding, J, Ng, IOL, Zhou, L   +10 more
core   +1 more source